我国首例侵入式脑机接口临床试验成功

Core Viewpoint - China's first prospective clinical trial of an invasive brain-computer interface (BCI) has been successfully conducted, making it the second country globally to enter the clinical trial phase after the United States [1] Group 1: Clinical Trial Details - The clinical trial's subject is a 37-year-old male who lost his limbs due to a high-voltage accident. Since the implantation of the BCI device in March, the system has operated stably without infections or electrode failures for over a month [3] - The subject has achieved a level of control over a computer touchpad comparable to that of a normal person, allowing him to play chess and racing games using only his thoughts after 2-3 weeks of adaptive training [3] Group 2: Technological Advancements - The implanted device is the smallest brain-controlled implant globally, measuring 26mm in diameter and less than 6mm in thickness, which is half the size of Neuralink's product [8] - The flexible neural electrodes developed by the research team are 1/5 to 1/7 the cross-sectional area of those used by Neuralink, providing better compatibility with brain tissue and reducing damage [5] Group 3: Research and Development - The research team has established a comprehensive approach to BCI research, covering various aspects such as motion perception, neural function repair, decoding algorithms, and wireless system development since 2022 [5] - The dynamic optimization of the neural decoder has been achieved through an online learning framework, allowing real-time motion decoding and overcoming the limitations of traditional static decoding models [9] Group 4: Future Prospects - The BCI system is expected to improve the quality of life for patients with complete spinal cord injuries, double upper limb amputations, and amyotrophic lateral sclerosis by enabling them to control external devices [12] - Future trials will aim to allow the subject to use robotic arms for physical tasks, expanding the potential applications of the technology [12]